S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
The “Perfect Storm” for Gold (Ad)
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Did You Get Your Free Bitcoin Yet? (Ad)
Intuitive Surgical Stock Can Trend Much Higher This Year 
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
Secret Bull Market Starts in This Unusual Sector (Ad)
3 Magnificent Seven Stocks Outperforming the Rest
Closing prices for crude oil, gold and other commodities
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
The “Perfect Storm” for Gold (Ad)
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Did You Get Your Free Bitcoin Yet? (Ad)
Intuitive Surgical Stock Can Trend Much Higher This Year 
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
Secret Bull Market Starts in This Unusual Sector (Ad)
3 Magnificent Seven Stocks Outperforming the Rest
Closing prices for crude oil, gold and other commodities
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
The “Perfect Storm” for Gold (Ad)
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Did You Get Your Free Bitcoin Yet? (Ad)
Intuitive Surgical Stock Can Trend Much Higher This Year 
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
Secret Bull Market Starts in This Unusual Sector (Ad)
3 Magnificent Seven Stocks Outperforming the Rest
Closing prices for crude oil, gold and other commodities
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
The “Perfect Storm” for Gold (Ad)
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Did You Get Your Free Bitcoin Yet? (Ad)
Intuitive Surgical Stock Can Trend Much Higher This Year 
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
Secret Bull Market Starts in This Unusual Sector (Ad)
3 Magnificent Seven Stocks Outperforming the Rest
Closing prices for crude oil, gold and other commodities
Free Trial
OTCMKTS:SPHDF

Santhera Pharmaceuticals (SPHDF) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)
Free SPHDF Stock Alerts
$11.70
0.00 (0.00%)
(As of 04/19/2024 ET)
Compare
Today's Range
$11.70
▼
$11.70
50-Day Range
$11.25
▼
$11.70
52-Week Range
$9.40
▼
$13.35
Volume
N/A
Average Volume
400 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisChartHeadlinesShort Interest
SPHDF stock logo

About Santhera Pharmaceuticals Stock (OTCMKTS:SPHDF)

Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally. The company's lead pipeline candidate includes Vamorolone, which is being developed for the treatments of Duchenne muscular dystrophy (DMD). Its clinical stage pipeline also comprises Lonodelestat to treat cystic fibrosis and other neutrophilic pulmonary diseases, as well as omigapil that treats congenital muscular dystrophies. The company also out-licenses outside North America and France rights to its approved product, Raxone (idebenone), for the treatment of Leber's hereditary optic neuropathy. Santhera Pharmaceuticals Holding AG was founded in 2004 and is headquartered in Pratteln, Switzerland.

SPHDF Stock Price History

SPHDF Stock News Headlines

March 27, 2024 | markets.businessinsider.com
Santhera : Vamorolone NDA Accepted For Priority Review By China' NMPA In Duchenne Muscular Dystrophy
March 27, 2024 | finance.yahoo.com
Santhera Announces NDA for Vamorolone in Duchenne Muscular Dystrophy Accepted and Granted Priority Review by China’s NMPA
April 20, 2024 | DTI (Ad)
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
February 14, 2024 | finance.yahoo.com
Santhera Announces Publication of Efficacy, Safety and Tolerability Data with Vamorolone (AGAMREE®) in Patients with Duchenne Muscular Dystrophy in Neurology
February 3, 2024 | morningstar.com
Santhera Pharmaceuticals Holding AG 0QN1
January 31, 2024 | finance.yahoo.com
Santhera Pharmaceuticals Holding AG (SANN.SW)
January 15, 2024 | finance.yahoo.com
Santhera Launches AGAMREE® (Vamorolone) in Germany as First Market for the Treatment of Duchenne Muscular Dystrophy
January 12, 2024 | markets.businessinsider.com
Analysts Offer Insights on Healthcare Companies: Santhera Pharmaceuticals Holding (OtherSPHDF), Ironwood Pharma (IRWD) and Cytokinetics (CYTK)
April 20, 2024 | DTI (Ad)
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
January 12, 2024 | finance.yahoo.com
Santhera Receives Approval for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy in the United Kingdom
December 18, 2023 | finance.yahoo.com
Santhera’s AGAMREE® (Vamorolone) Approved in the European Union for the Treatment of Duchenne Muscular Dystrophy
December 7, 2023 | finance.yahoo.com
Santhera Appoints Executive Committee Members as it Transitions into Commercial Stage
October 27, 2023 | finance.yahoo.com
Santhera Receives U.S. FDA Approval of AGAMREE® (vamorolone) for the Treatment of Duchenne Muscular Dystrophy
October 26, 2023 | reuters.com
US FDA approves Santhera's Duschenne drug
October 13, 2023 | markets.businessinsider.com
Santhera: Europe's CHMP Issues Positive Opinion For AGAMREE To Treat Duchenne Muscular Dystrophy
October 13, 2023 | markets.businessinsider.com
Positive European Approval Outlook for Santhera’s AGAMREE Bolsters Buy Rating: Potential Milestone for DMD Treatment
October 13, 2023 | finance.yahoo.com
Santhera Receives Positive CHMP Opinion Recommending Approval of AGAMREE® (vamorolone) for the Treatment of Duchenne Muscular Dystrophy
September 8, 2023 | seekingalpha.com
Santhera Pharmaceuticals reports 1H results
September 8, 2023 | finance.yahoo.com
Santhera Pharmaceuticals Holding AG (VTX:SANN) Is About To Turn The Corner
September 7, 2023 | finance.yahoo.com
Santhera Announces Half-Year 2023 Financial Results and Provides Corporate Update
July 31, 2023 | benzinga.com
Santhera Completes Divestment of Raxone®/Idebenone Business to Chiesi Group
July 31, 2023 | markets.businessinsider.com
H.C. Wainwright Keeps Their Buy Rating on Santhera Pharmaceuticals Holding (SPHDD)
June 29, 2023 | finanznachrichten.de
Santhera Pharmaceuticals Holding AG: Santhera Publishes Timeline of the Reverse Share Split
June 29, 2023 | finance.yahoo.com
Santhera Publishes Timeline of the Reverse Share Split
June 27, 2023 | finanznachrichten.de
Santhera Pharmaceuticals Holding AG: Shareholders Approve all Board Proposals at Today's Annual General Meeting
June 27, 2023 | finance.yahoo.com
Shareholders Approve all Board Proposals at Today’s Annual General Meeting
June 21, 2023 | msn.com
Catalyst (CPRX) to Gain DMD Drug Licensing Rights From Santhera
See More Headlines
Receive SPHDF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Santhera Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
OTCMKTS:SPHDF
CUSIP
N/A
CIK
N/A
Web
www.santhera.com
Phone
(161) 906-8950
Fax
N/A
Employees
45
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A
A Guide To High-Short-Interest Stocks Cover
A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Thomas Meier Ph.D. (Age 62)
    Founder & Chairman
    Comp: $91.83k
  • Mr. Dario Eklund (Age 56)
    Chief Executive Officer
    Comp: $893.47k
  • Mr. Andrew P. Smith CGMA (Age 62)
    FCMA, Chief Financial Officer
  • Mr. Oliver Strub (Age 61)
    General Counsel & Secretary
  • Mr. Günther Metz Ph.D. (Age 66)
    Head Business Development
  • Mr. Shabir Hasham M.D.
    Chief Medical Officer
  • Mr. Marc Schrader
    Chief Technology Officer
  • Ms. Eva Kalias
    Head of Investor Relations & Communications
  • Mr. Neville Kodkani M.D.
    Head of Global Marketing & Partner Management
  • Ms. Sarah Holmes-Klotz
    Head of People & Culture

Key Competitors

View All Competitors

SPHDF Stock Analysis - Frequently Asked Questions

How have SPHDF shares performed in 2024?

Santhera Pharmaceuticals' stock was trading at $11.70 at the beginning of the year. Since then, SPHDF stock has increased by 0.0% and is now trading at $11.70.
View the best growth stocks for 2024 here.

When did Santhera Pharmaceuticals' stock split?

Santhera Pharmaceuticals shares reverse split on the morning of Monday, July 3rd 2023. The 1-10 reverse split was announced on Monday, July 3rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, July 3rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

How do I buy shares of Santhera Pharmaceuticals?

Shares of SPHDF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:SPHDF) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners
The “Perfect Storm” for Gold
Gold Safe Exchange
Biden’s $374B Giveaway Into This Sector
DTI
SHOCKING Crypto Leak…
Crypto 101 Media
Your Money is Not Safe
American Alternative
The #1 Crypto for 2024
InvestorPlace
Did You Get Your Free Bitcoin Yet?
Crypto Swap Profits
Urgent alert: open this for a huge profit potential
Timothy Sykes
Tiny Biotech Stock Wins $75 Billion Patent
Behind the Markets